Literature DB >> 34983925

The role of teprotumumab in chronic, clinically active thyroid eye disease.

Caroline Y Yu1, Brittany A Simmons1, Chau M Pham1, Erin M Shriver2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34983925      PMCID： PMC9232635          DOI： 10.1038/s41433-021-01904-4

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   4.456


× No keyword cloud information.
  4 in total

1.  Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.

Authors:  Shoaib Ugradar; Lu Shi; Yao Wang; Tunde Mester; Huasheng Yang; Raymond S Douglas
Journal:  Eye (Lond)       Date:  2020-11-21       Impact factor: 4.456

2.  Teprotumumab for chronic thyroid eye disease.

Authors:  Daniel J Ozzello; Liane O Dallalzadeh; Catherine Y Liu
Journal:  Orbit       Date:  2021-06-01

3.  Early experience with teprotumumab for chronic thyroid eye disease.

Authors:  Daniel J Ozzello; Don O Kikkawa; Bobby S Korn
Journal:  Am J Ophthalmol Case Rep       Date:  2020-05-15

4.  Teprotumumab for the treatment of chronic thyroid eye disease.

Authors:  Shoaib Ugradar; Julia Kang; Andrea L Kossler; Erin Zimmerman; Jenna Braun; Andrew R Harrison; Swaraj Bose; Kimberly Cockerham; Raymond S Douglas
Journal:  Eye (Lond)       Date:  2021-07-09       Impact factor: 4.456
  4 in total
  1 in total

Review 1.  Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.

Authors:  Caroline Y Yu; Rebecca L Ford; Sara T Wester; Erin M Shriver
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.